News & Articles

1 in 3 Phase II trials were terminated in 2024

The UG 100 offers a cost-effective and extremely low-error sequencing profile

By developing rapid, accurate, and cost-effective lateral flow tests for prostate cancer, Valley Diagnostics aims to make early diagnosis more accessible and reliable

Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques

Drug Discovery returns to Liverpool, 21–22 October 2025 to celebrate 'A Festival of Life Science'

The Adeno-Associated Virus will be used in a Phase 1 trial in patients with advanced, high-risk acute myeloid leukemia.

Hear expert insights on ADC innovations, manufacturing challenges, and the future of precision medicine

New test format enhances commercialisation potential

Successful project delivery of Optimer binders with proven function as vaccine adjuvants

As scientists uncover more links between gut bacteria and cancer, microbiome testing offers a promising approach to detect, treat, and even prevent the disease

Since 2021, only 14% of rivers in England achieved ‘good’ ecological status and none received an overall ‘good’ classification from the Environment Agency

Dr. Murakami discusses the molecular tools enabling the pursuit of precision medicine

Technology advances, coupled with collaborations between equipment makers and healthcare organizations, are improving early detection of blood cancers in Africa

Vote for the product that has made the most difference to your lab for the chance to win a $100 Amazon Gift Card (or equivalent currency)

Accuracy in ESR1 mutation testing means the difference between treatment and resistance — now a new ESR1 control kit ensures reliable results

From spreadsheet silos to AI-powered insights, discover how Signals software is streamlining formulation science

Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling

The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment

Grifols and IBL, a Tecan company, seek to revolutionize clinical diagnostics with a future high-sensitivity, multiplexed immunoassay platform

Breakthrough status provides expedited review and closer collaboration with the FDA, ultimately enabling broader market reach and commercial adoption

Redipor by AnalytiChem combining 150+ years of expertise in high-quality prepared media, now manufactured in three production facilities worldwide